impact of recession on your business
Point of Care Diagnostics/Testing Market

Point of Care Diagnostics/Testing Market Size, Share & Segmentation by Mode of Purchase (OTC, Prescription-based), by Platform (Immunoassays, Molecular Diagnostics, Dipsticks), by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Hematology Testing, Cancer/Tumor Marker Testing, Urinalysis Testing, Cholesterol, Drugs-of-Abuse Testing), by End User (Hospitals & Clinics, Diagnostic Centers, Homecare/Self Testing), by Region, and Global Forecast 2023-2030

Report Id: SNS/HC/2596 | July 2022 | Region: Global | 126 Pages

Report Scope & Overview:

The Point of Care Diagnostics/Testing Market Size was valued at USD 23.99 billion in 2022 and is expected to reach USD 58.97 billion by 2030, and grow at a CAGR of  11.9% over the forecast period 2023-2030.

Point of care diagnostics/testing is a type of health analysis that is performed near the patient and does not require a laboratory environment. Point of care (POC) testing is also known as near-patient testing, bedside testing, mobile testing, remote testing, and rapid diagnosis. The approach is used to diagnose infectious diseases in areas with little healthcare infrastructure. A point-of-care (POC) diagnostic device collects specific clinical data from patients in clinical and resource-limited scenarios. Traditional clinical diagnostic techniques demand high-end and costly tools, a professional technician for operation and result interpretation, and more time, all of which depletes and costs money.

Point of Care Diagnostics/Testing Market

Despite substantial improvements in medical facilities in various regions' healthcare systems, the use of POC diagnostic equipment is still in its infancy.



  • Globally, the number of chronic disease cases is increasing.

  • There is an increasing demand for AI-integrated proof-of-concepts for real-time diagnostics.


  • The multi-layered rules imposed by international governing bodies such as the FDA and CLIA are limiting the market expansion of POC producers and creating a regulatory barrier in the promotion and sale of their goods.

  • Healthcare device producers must submit performance data for their products, detailing the benefits and drawbacks of the product on the persons who have been tested.


  • The challenge that manufacturers face is deploying their products in accordance with regional authorities.


The pandemic epidemic halted operations in all sectors around the world. During the initial period of the lockdown, the healthcare industry was particularly heavily hit. Medical supplies were stacked up in huge quantities, and the number of manufactured goods increased as the supply chain within and across borders was severely disrupted by the adoption of the safety requirements. However, as the number of impacted patients decreased, regulatory authorities permitted restricted mobility and manufacturing of vital products. The loosening of rules boosted demand for healthcare items that serve the point-of-care diagnostics/testing sector.

During the pandemic, market participants invested much in the development of fast testing for COVID-19 diagnosis. According to WHO, the industry participants will collaborate in September 2020 to develop 120 million economic antigen-based quick diagnostic POC tests for developing countries. The Bill & Melinda Gates Foundation (US), SD BioSensor Inc. (South Korea), and Abbott Laboratories (US) agreed to offer the POC test products for a maximum of USD 5. The Global Fund provided USD 50 million to help low- and middle-income countries (LMICs) purchase the diagnostic test. Furthermore, the FDA authorised the POC antibody test for COVID-19 in September 2020, which will allow patients to understand their health condition and determine whether the virus has infected them or not.

Furthermore, regulatory agencies modified their point-of-care and quick testing criteria for SARS-CoV-2. These enabling factors boosted market expansion and are likely to increase during the forecast period. Glucose Testing It is a device that measures the concentration of glucose in the blood using a lancet, metre, or other device. Cardiometabolic Testing It is a sort of monitoring device that measures the risk associated with cardiovascular functions such as blood pressure, blood gas, blood fat, LDL (low-density lipoprotein) levels, and so on.

Testing for Infectious Diseases It is a gadget that identifies diseases caused by organisms like viruses, bacteria, and fungi. Coagulation Testing It is a gadget that evaluates blood clotting capacity. It will provide valuable information to clinicians on the proper deployment of clotting factor in the bleeding area. Fertility and pregnancy testing It is a device that assesses both men and women's potential to conceive naturally as well as the existence of any sexually transmitted infections.

Hematology Examination These machines do blood tests to assess total blood count, protein levels, infection, inflammation, blood-clotting disorders, anaemia, and leukaemia. Cancer/Tumor Marker Analysis It is a gadget that detects tumour markers in blood, tissue, urine, and other bodily fluids. The device monitors the protein and other chemicals produced in response to tumour cells. Urinalysis Examination This gadget detects kidney abnormalities, diabetes levels, liver difficulties, and other metabolic functions, as well as diagnoses urinary tract infections. Cholesterol It is a gadget that detects high-density and low-density proteins as well as specific lipids in the blood.

Abuse Examination It is a non-medical equipment that detects illegal chemicals in urine, saliva, blood, hair, and perspiration. Hospitals and Clinics Hospitals and Clinics are organisations that provide medical and surgical care to the injured. Diagnostic Facilities It is a facility that provides diagnostic services to the general public and medical practitioners. Self-Testing at Home It is professional caregiver healthcare help provided to patients in their homes for health services. OTC Testing Supplies It is a test that does not require a prescription and is not limited to specific healthcare settings.

Prescription-only testing solutions It is a type of test that is performed depending on a doctor's prescription. Immunoassays It is a platform for measuring specific proteins and auxiliary chemicals based on their antigen and antibody characteristics. Molecular Testing It is a platform for identifying disease through the use of molecules such as DNA, RNA, tissue, fluid, and proteins. Dipsticks It is a chemically integrated sensitive strip of paper that detects glucose, protein, and other urinary components.


Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., PTS Diagnostics, Nova Biomedical, QuidelCorporation, Abbott Laboratories, Siemens Healthineers GmbH, Chembio Diagnostics, Inc., Becton, Dickinson and Company, Danaher Corporation.


by End User

  • Hospitals & Clinics

  • Diagnostic Centers

  • Homecare/Self Testing

  • Others

by Mode of Purchase

  • OTC Testing Products

  • Prescription-based testing products

by Platform

  • Immunoassays

  • Molecular Diagnostics

  • Dipsticks

  • Others

by Product

  • Glucose Monitoring

  • Cardiometabolic Monitoring

  • Infectious Disease Testing

  • Coagulation Monitoring

  • Pregnancy & Fertility Testing

  • Hematology Testing

  • Cancer/Tumor Marker Testing

  • Urinalysis Testing

  • Cholesterol

  • Drugs-of-Abuse Testing

  • Others

Point of Care Diagnostics/Testing Market


North America held the highest share of the point of care diagnostics/testing market in 2021, owing to an increasing number of market players across the region, acquisitions of industry players by healthcare behemoths, and favourable government regulations. Healthcare product providers are merging and acquiring current market participants in order to expand their product availability across the region. For business expansion, market participants are implementing business strategies such as the launch of new products, R&D activities, and collaborative product creation.

Due to restricted healthcare staff availability, diverse manufacturing facilities, changing demographics, and increasing consumer healthcare expectations, the Asia-Pacific point of care diagnostics/testing market is expected to be the fastest-growing regional market. Furthermore, comforting government rules, significant funding from industry participants, and technologically advanced product innovation are all elements boosting the point of care diagnostics/testing market.


  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America


Point of Care Diagnostics/Testing Market Report Scope:
Report Attributes Details
Market Size in 2022 US$ 23.99 Billion
Market Size by 2030 US$ 58.97 Billion
CAGR CAGR of 11.9% From 2023 to 2030
Base Year 2022
Forecast Period 2023-2030
Historical Data 2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • by Mode of Purchase (OTC, Prescription-based)
• by Platform (Immunoassays, Molecular Diagnostics, Dipsticks)
• by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Hematology Testing, Cancer/Tumor Marker Testing, Urinalysis Testing, Cholesterol, Drugs-of-Abuse Testing)
• by End User (Hospitals & Clinics, Diagnostic Centers, Homecare/Self Testing)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., PTS Diagnostics, Nova Biomedical, QuidelCorporation, Abbott Laboratories, Siemens Healthineers GmbH, Chembio Diagnostics, Inc., Becton, Dickinson and Company, Danaher Corporation.
Key Drivers • Globally, the number of chronic disease cases is increasing.
RESTRAINTS • Healthcare device producers must submit performance data for their products, detailing the benefits and drawbacks of the product on the persons who have been tested.

Frequently Asked Questions (FAQ) :

Table of Contents


1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions


2. Research Methodology


3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges


4. Impact Analysis

4.1 COVID-19 Impact Analysis

4.2 Impact of Ukraine- Russia war

4.3 Impact of ongoing Recession

4.3.1 Introduction

4.3.2 Impact on major economies US Canada Germany France United Kingdom China Japan South Korea Rest of the World


5. Value Chain Analysis


6. Porter’s 5 forces model


7.  PEST Analysis


8. Point of Care Diagnostics/Testing Market, by End User

8.1 Hospitals & Clinics

8.2 Diagnostic Centers

8.3 Homecare/Self Testing

8.4 Others


9.Point of Care Diagnostics/Testing Market, by Mode of Purchase

9.1 OTC Testing Products

9.2 Prescription-based testing products


10.Point of Care Diagnostics/Testing Market, by Platform

10.1 Immunoassays

10.2 Molecular Diagnostics

10.3 Dipsticks

10.4 Others


11.Point of Care Diagnostics/Testing Market, by Product

11.1 Glucose Monitoring

11.2 Cardiometabolic Monitoring

11.3 Infectious Disease Testing

11.4 Coagulation Monitoring

11.5 Pregnancy & Fertility Testing

11.6 Hematology Testing

11.7 Cancer/Tumor Marker Testing

11.8 Urinalysis Testing

11.9 Cholesterol

11.10 Drugs-of-Abuse Testing

11.11 Others


12. Regional Analysis

12.1 Introduction

12.2 North America

12.2.1 USA

12.2.2 Canada

12.2.3 Mexico

12.3 Europe

12.3.1 Germany

12.3.2 UK

12.3.3 France

12.3.4 Italy

12.3.5 Spain

12.3.6 The Netherlands

12.3.7 Rest of Europe

12.4 Asia-Pacific

12.4.1 Japan

12.4.2 South Korea

12.4.3 China

12.4.4 India

12.4.5 Australia

12.4.6 Rest of Asia-Pacific

12.5 The Middle East & Africa

12.5.1 Israel

12.5.2 UAE

12.5.3 South Africa

12.5.4 Rest

12.6 Latin America

12.6.1 Brazil

12.6.2 Argentina

12.6.3 Rest of Latin America


13.Company Profiles

13.1 Hoffmann-La Roche Ltd

13.1.1 Financial

13.1.2 Products/ Services Offered

13.1.3 SWOT Analysis

13.1.4 The SNS view

13.2 Johnson & Johnson Services, Inc.

13.3 PTS Diagnostics

13.4 Nova Biomedical

13.5 QuidelCorporation

13.6 Abbott Laboratories

13.7 Siemens Healthineers GmbH

13.8 Chembio Diagnostics, Inc.

13.9 Becton, Dickinson and Company

13.10 Danaher Corporation


14. Competitive Landscape

14.1 Competitive Benchmarking

14.2 Market Share analysis

14.3 Recent Developments


15. Conclusion


An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.


The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.

Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.